Aegis Capital Starts Rosetta Genomics (ROSG) at Buy, PT of $3.50

Aegis Capital starts Rosetta Genomics, Ltd. (ROSG) with a Buy rating and $3.50 price target.

Analyst Robert LeBoyer noted:

• Rosetta Genomics has built a genetic testing business that began with its proprietary microRNA (miRNA) technology. MicroRNAs are made early in the process of transcription from DNA to proteins, and have a role in the regulation of gene expression. This gives Rosetta's microRNA diagnostics greater accuracy and more predictive value than tests based on other biological markers. The company has been building its diagnostic business through acquisition and internal development of diagnostic tests using Next-Generation Sequencing, and FISH (fluorescence in situ hybridization) testing.
• Rosetta's diagnostics can detect identify changes in the genetic information in the tissue samples that are used to determine which genes are present in a sample. This can determine if the cells are cancerous, as well as the specific mutation that is causing the cancer. This information is used to select the best drug to treat that specific tumor.
• On reimbursement charges: Selecting the right drug for the patient's tumor type is more effective and improves outcomes for the patients. Improving the response rates also avoids the cost of failed chemotherapy regimens. Some new chemotherapy drugs are targeted to tumors with specific mutations, so that genetic profiling may be required to qualify the patients for treatment. Medicare and private payers have been changing their policies to provide more favorable reimbursement to help improve the patient outcomes while lowering their costs.

For an analyst ratings summary and ratings history on Rosetta Genomics click here. For more ratings news on Rosetta Genomics click here.

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Oppenheimer Starts Carriage Services (CSV) at Outperform
• Evercore ISI Starts Alvotech SA (ALVO) at Outperform